SEK 615.00
-2.50 (-0.40%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CAMX.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 observational · 4 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Observational Study of Octreotide Subcutaneous Depot in Patients With AcromegalyNCT07583563observationalIncidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information. | — | Recruiting | Drug: Octreotide subcutaneous depot | Acromegaly | 200 | Jun 2029 | ≤ 1,046 d | 2026-08-12 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETNCT05050942Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: CAM2029, Octreotide LAR, Lanreotide ATG | Gastro-enteropancreatic Neuroendocrine Tumor | 332 | Nov 2026 | ≤ 103 d | 2026-07-28 |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDNCT05281328results2026-06-01Height-adjusted Total Liver Volume (htTLV)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Active, not recruiting | Drug: CAM2029, Placebo | Polycystic Liver Disease | 71 | 2025-02-05actual | — | 2026-06-01 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyNCT04125836Characterization of adverse events (AEs)Open-label · Treatment | Phase 3 | Completed | Drug: CAM2029 (octreotide subcutaneous depot) | Acromegaly | 135 | 2025-04-24actual | — | 2025-12-22 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyNCT04076462Proportion of patients with mean IGF-1 levels ≤1xULNRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: CAM2029 (octreotide subcutaneous depot), Matching placebo | Acromegaly | 72 | 2023-05-02actual | — | 2024-04-25 |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)NCT02299089results2017-12-15Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUCRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: octreotide FluidCrystal® injection depot | Acromegaly, Neuroendocrine Tumors | 12 | May 2016actual | — | 2017-12-15 |
| Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate CancerNCT02212197results2017-02-06Observed Maximum Serum Leuprolide Concentration (Cmax) for Dose 1 and Dose 3Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: leuprolide acetate FluidCrystal® injection depot, leuprolide acetate | Prostate Cancer | 51 | Nov 2015actual | — | 2017-04-25 |
| A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral MucositisNCT01684566results2016-03-14WHO (World Health Organisation) Oral Mucositis Severity Score During 28 Days of Treatment, Intention to Treat PopulationRandomized · Open-label · Supportive care | Not applicable | Completed | Device: episil(R) · Other: Oral hygiene procedures | Oral Mucositis | 116 | Sep 2013actual | — | 2016-03-14 |
| Effects of Mucoprotective Product on XerostomiaNCT01316393OHIP questionaire health impact profileRandomized · Single-masked · Supportive care | Phase 4 | Completed | Other: XER2020 | Xerostomia | 20 | May 2011actual | — | 2011-11-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19